Skip to main content
Top
Published in: Clinical and Translational Oncology 2/2018

01-02-2018 | Brief Research Article

Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma

Authors: M. L. Sánchez de Molina, C. Díaz del Arco, P. Vorwald, D. García-Olmo, L. Estrada, M. J. Fernández-Aceñero

Published in: Clinical and Translational Oncology | Issue 2/2018

Login to get access

Abstract

Background

Neoadjuvant therapy (NAT) is a useful therapeutic option. However, some patients respond poorly to it and can even show tumor progression. It is important to define factors that can predict response to NAT.

Materials and methods

This is a retrospective cohort study to define histopathological factors predicting response to NAT in gastric tubular carcinoma. This study has enrolled 80 patients receiving chemotherapy for locally advanced gastric carcinoma.

Results

44.5% of the patients were men; mean age was 64.49 years. Only 5.7% of the patients showed a complete response to therapy, 10% had grade 1, 21.4% grade 2, and 62.9% grade 3 regression. On follow-up, 43.8% of the patients showed recurrence of disease (57.1% distant metastasis) and 33.8% eventually died of it. We found a statistically significant association between response and prognosis. We found a statistically significant association between regression and perineural, vascular, and lymph vessel invasion. Logistic regression model showed that only lymph vessel invasion had independent influence. Lymph vessel invasion not only indicated lack of response to therapy, but also higher incidence of lymph node involvement in the gastrectomy specimen.

Discussion

Our study indicates that the presence of vascular or perineural invasion in the endoscopic biopsies and high histopathological grade predict poor response to therapy. This seems peculiar, for undifferentiated tumors are supposed to have better response to therapy.

Conclusion

Our study indicates that undifferentiated tumors respond worse to therapy. Furthermore, studies are necessary to define lack of response, to help avoid neoadjuvant therapy in unfavorable cases.
Literature
1.
go back to reference Salem ME, Hartley M, Unger K, Marshall JL. Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its future direction. Oncology (Williston Park). 2016;30:546–62. Salem ME, Hartley M, Unger K, Marshall JL. Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its future direction. Oncology (Williston Park). 2016;30:546–62.
2.
go back to reference Boland PM, Fakih M. The emerging role of neoadjuvant chemotherapy for rectal cancer. J Gastrointestinal Oncol. 2014;5:362–73. Boland PM, Fakih M. The emerging role of neoadjuvant chemotherapy for rectal cancer. J Gastrointestinal Oncol. 2014;5:362–73.
3.
go back to reference Russell MC. Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer. J Surg Oncol. 2016;. doi:10.1002/jso.24293. Russell MC. Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer. J Surg Oncol. 2016;. doi:10.​1002/​jso.​24293.
5.
go back to reference Metha RS. Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer. J Clin Oncol. 2008;19:3286–8. Metha RS. Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer. J Clin Oncol. 2008;19:3286–8.
6.
go back to reference Gray J, Sommers E, Alvelo-Rivera M, Robinson L, Bepler G. Neoadjuvant therapy for resectable non-small cell lung cancer. Oncology (Willinston Park). 2009;23:879–86. Gray J, Sommers E, Alvelo-Rivera M, Robinson L, Bepler G. Neoadjuvant therapy for resectable non-small cell lung cancer. Oncology (Willinston Park). 2009;23:879–86.
7.
go back to reference Shuberth CR, Bergquist JR, Groeschl RT, Habermann EB, Wilson PM, Truty MJ, et al. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: an intention to treat analysis of the National Cancer Database. Surgery. 2016;. doi:10.1016/j.surg.2016.06.010. Shuberth CR, Bergquist JR, Groeschl RT, Habermann EB, Wilson PM, Truty MJ, et al. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: an intention to treat analysis of the National Cancer Database. Surgery. 2016;. doi:10.​1016/​j.​surg.​2016.​06.​010.
8.
go back to reference Kim SH, Chang HJ, Kim DY, Park JW, Baek JY, Kim SY, et al. What is the ideal regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Can Res Treat. 2016;48:998–1009.CrossRef Kim SH, Chang HJ, Kim DY, Park JW, Baek JY, Kim SY, et al. What is the ideal regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Can Res Treat. 2016;48:998–1009.CrossRef
9.
go back to reference Ryan JE, Warrier SK, Lynch AC, Ramsay RG, Phillips WA. Heriot AG predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2016;18(3):234–46. doi:10.1111/codi.13207.CrossRefPubMed Ryan JE, Warrier SK, Lynch AC, Ramsay RG, Phillips WA. Heriot AG predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2016;18(3):234–46. doi:10.​1111/​codi.​13207.CrossRefPubMed
10.
go back to reference Toxopeus EL, Nieboer D, Shapiro J, Biermann K, van der Gaast A, van Rij CM, et al. Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer. Radiother Oncol. 2015;115(3):392–8. doi:10.1016/j.radonc.2015.04.028 (Epub 2015 Ju).CrossRefPubMed Toxopeus EL, Nieboer D, Shapiro J, Biermann K, van der Gaast A, van Rij CM, et al. Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer. Radiother Oncol. 2015;115(3):392–8. doi:10.​1016/​j.​radonc.​2015.​04.​028 (Epub 2015 Ju).CrossRefPubMed
11.
go back to reference Sun W, Li G, Wan J, Zhu J, Shen W, Zhang Z. Circulating tumor cells: a promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget. 2016;. doi:10.18632/oncotarget.10875. Sun W, Li G, Wan J, Zhu J, Shen W, Zhang Z. Circulating tumor cells: a promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget. 2016;. doi:10.​18632/​oncotarget.​10875.
12.
go back to reference Tromberg BJ, Zhang Z, Leproux A, O’Sullivan TD, Cerussi AE, Carpenter PM, et al. Predicting responses to neoadjuvant chemotherapy in Breast Cancer: ACRIN 6691 trial of diffuse optical spectroscopic imaging (DOSI). Cancer Res. 2016;76(20):5933–44.CrossRefPubMedPubMedCentral Tromberg BJ, Zhang Z, Leproux A, O’Sullivan TD, Cerussi AE, Carpenter PM, et al. Predicting responses to neoadjuvant chemotherapy in Breast Cancer: ACRIN 6691 trial of diffuse optical spectroscopic imaging (DOSI). Cancer Res. 2016;76(20):5933–44.CrossRefPubMedPubMedCentral
13.
go back to reference Gómez Del Pulgar T, Cebrián A, Fernández-Aceñero MJ, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, et al. Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer. J Cell Mol Med. 2016;20(9):1729–36. doi:10.1111/jcmm.12879 (Epub 2016 May 12).CrossRefPubMedPubMedCentral Gómez Del Pulgar T, Cebrián A, Fernández-Aceñero MJ, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, et al. Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer. J Cell Mol Med. 2016;20(9):1729–36. doi:10.​1111/​jcmm.​12879 (Epub 2016 May 12).CrossRefPubMedPubMedCentral
14.
go back to reference Li S, Li J, Liu Z, Zhang Z, Zhang W, Yang H, et al. Predictive value of P53, Ki-67, HER2 protein detection in neoadjuvant chemotherapy for adenocarcinoma of gastroesophageal junction. Zhonghua Wei Chang Wai Ke Za Zhi. 2015;18(9):901–4.PubMed Li S, Li J, Liu Z, Zhang Z, Zhang W, Yang H, et al. Predictive value of P53, Ki-67, HER2 protein detection in neoadjuvant chemotherapy for adenocarcinoma of gastroesophageal junction. Zhonghua Wei Chang Wai Ke Za Zhi. 2015;18(9):901–4.PubMed
15.
go back to reference Tang L, Li ZY, Li ZW, Zhang XP, Li YL, Li XT, et al. Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clin Radiol. 2015;70(11):1198–204. doi:10.1016/j.crad.2015.06.083 (Epub 2015 Jul 15).CrossRefPubMed Tang L, Li ZY, Li ZW, Zhang XP, Li YL, Li XT, et al. Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clin Radiol. 2015;70(11):1198–204. doi:10.​1016/​j.​crad.​2015.​06.​083 (Epub 2015 Jul 15).CrossRefPubMed
17.
go back to reference Figueiredo C, Camargo MC, Leite M, Fuentes-Pananá EM, Rabkin CS, Machado JC. Pathogenesis of gastric cancer: genetics and molecular classification. Curr Top Microbiol Immunol. 2017;400:277–304. doi:10.1007/978-3-319-50520-6-12.PubMed Figueiredo C, Camargo MC, Leite M, Fuentes-Pananá EM, Rabkin CS, Machado JC. Pathogenesis of gastric cancer: genetics and molecular classification. Curr Top Microbiol Immunol. 2017;400:277–304. doi:10.​1007/​978-3-319-50520-6-12.PubMed
18.
go back to reference Neves Filho EH, de Sant’Ana RO, Nunes LV, Pires AP, da Cunha MD. Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. APMIS. 2017;125(2):79–84. doi:10.1111/apm.12642 (Epub 2017 Jan 2).CrossRefPubMed Neves Filho EH, de Sant’Ana RO, Nunes LV, Pires AP, da Cunha MD. Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. APMIS. 2017;125(2):79–84. doi:10.​1111/​apm.​12642 (Epub 2017 Jan 2).CrossRefPubMed
Metadata
Title
Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma
Authors
M. L. Sánchez de Molina
C. Díaz del Arco
P. Vorwald
D. García-Olmo
L. Estrada
M. J. Fernández-Aceñero
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 2/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1707-1

Other articles of this Issue 2/2018

Clinical and Translational Oncology 2/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine